San Antonio Breast Cancer Symposium 2015. Dec.8-12

I think the reason there won’t be much more data on TailoRx yet is because they are still trying to crunch the data on postmenopausal women with Oncotype scores from 11-17 and didn’t opt for chemo; they may find much the same results as with those who scored <10.

Sandy, wasn't part of the issue that there have not been enough events in the 11-25 range to draw any conclusions yet?

With over 1400 papers accepted and a plethora of presentations/discussions, keeping up with the various Twitter feeds is mind numbing.

Here's one that I thought was interesting.

"Women with Luminal A breast cancer derive no benefit from adjuvant chemo."
Despite several limitations to their study, researchers analyzed data from the DBCG 77B trial (started in 1977) and found that Adjuvant chemo conferred no long-term DFS benefit to premenopausal women with invasive Luminal A breast cancer.

The study’s authors admitted that the chemo drugs they used were earlier-generation (CMF) therapy--the study didn’t include women getting anthracyclines or taxanes, more commonly used today in conjunction with Cytoxan, nor those HER2+ getting targeted therapy, and ER+ women getting endocrine therapy. So OncotypeDX and MammoPrint are still more reliable predictors.

MO is at this conference also.

"Avelumab Effective in PD-L1-Positive Metastatic Breast Cancer"
Avelumab is a monoclonal antibody (mAb) directed against the PD-L1 protein, with potential immune checkpoint inhibitory and antineoplastic activities. This immunotherapy was effective in PD-L1-positive metastatic patients, particularly for the triple-negative cohort.
These results come from a small Phase IB trial, enrolling 168 patients.

Re: the denosumab study--surprised at the very low incidence of SEs that wouldn’t have been expected with AIs alone. Guess I may have to put up with a few days of fever twice a year, if it keeps me from breaking my hips & spine; the anti-cancer benefit would be lagniappe.